PARP inhibitor | Olaparib | Rucaparib | Niraparib | Talazoparib | Veliparib |
---|---|---|---|---|---|
Approvals | Ovarian cancer Breast cancer | Ovarian cancer | Ovarian cancer | Ovarian cancer | Not approved |
PARP trapping potency | Middle | Middle | Middle | High | Low |
Recommended dose | 300Â mg BID | 600Â mg BID | 300Â mg BID | 1Â mg QD | 600Â mg BID |
The most common adverse reactions (in at least 20% patients) | Anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, arthralgia/myalgia, dysgeusia, headache, dyspepsia, decreased appetite, constipation, and stomatitis | Nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea | Nausea, thrombocytopenia, fatigue, anemia, constipation, vomiting, neutropenia, headache, decreased appetite, insomnia, abdominal pain | Fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, decreased appetite | Nausea, fatigue |